← Back to Search

Integrase Inhibitor

Continue on non-integrase inhibitor based regimen for Vascular Disease

Phase 4
Waitlist Available
Led By Jonell B Poe, MPAS
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age greater than or equal to 18 years with HIV-1 who have been virologically suppressed (HIV-1 RNA < 50 copies for greater than or equal to 3 months on a non-integrase strand transfer inhibitor-based regimen
Have the ability to understand and sign an informed consent written in the English language
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This trial will compare the effects of two different HIV medication regimens on various health outcomes.

Eligible Conditions
  • Vascular Disease
  • HIV
  • Antiviral Drug Reaction
  • Weight Changes
  • Obesity
  • Lipodystrophy Syndrome
  • Cardiovascular Abnormalities

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Weight
Secondary outcome measures
Change in body mass index (BMI)
Change in vascular endothelial function
Height
Other outcome measures
Change in HIV-1 RNA viral load
Change in cholesterol
Change in fasting serum glucose level
+4 more

Trial Design

2Treatment groups
Active Control
Group I: Continue on non-integrase inhibitor based regimenActive Control1 Intervention
Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
Group II: Switch from a non-integrase based regimen to dolutegravirActive Control1 Intervention
Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.

Find a Location

Who is running the clinical trial?

Augusta UniversityLead Sponsor
210 Previous Clinical Trials
85,046 Total Patients Enrolled
Jonell B Poe, MPASPrincipal InvestigatorAugusta University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025